$Pfizer(PFE)$The latest data from Pfizer shows that the effective rate of the new crown oral drug Paxlovid in reducing hospitalization or mortality is still 89%, and in vitro tests have confirmed that it is still effective for Omicron. In addition, a South African study showed that two doses of the BioNTech/Pfizer vaccine are effective in preventing admission of patients with Omicron infection by 70%.
Pfizer said on Tuesday that its new crown oral drug Paxlovid is nearly 90% effective in preventing hospitalization and death of high-risk patients, and recent experimental data shows that the oral drug still has an effect on the fast-spreading poison king Omicron.
The release of these positive data results comes at a time when the U.S. Food and Drug Administration (FDA) is reviewing whether to approve the use of paxlovid in high-risk adults. The researchers are satisfied with these data. Mikael dolsten, Pfizer's chief scientific officer, said in an interview: "this is a complete victory and brings great hope for another effective defense against the virus."
精彩评论